There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Patricia A. Turney net worth and biography

Patricia Turney Biography and Net Worth

SVP of Arcutis Biotherapeutics

Ms. Turney has served as our senior vice president, operations since January 2020. She previously worked at Amgen, Inc. from 1996 to 2019 in roles of increasing responsibility, most recently as vice president, external supply, where she managed more than 50 contract manufacturing sites supporting clinical programs and commercial products. Prior Amgen roles included: executive director, medical device and direct materials; site operations head for Amgen’s Netherlands site; executive director, global facilities operations; and director, R&D strategic operations. Prior to joining Amgen, Ms Turney was a Federal Aviation Administration certified instructor, and earlier, a naval aviator in the United States Navy. She holds a Bachelor of Science in mathematics from the United States Naval Academy and a Master of Business Administration from the Anderson School, University of California, Los Angeles.

What is Patricia A. Turney's net worth?: The estimated net worth of Patricia A. Turney is at least $582,102.12 as of March 6th, 2023. Ms. Turney owns 62,862 shares of Arcutis Biotherapeutics stock worth more than $582,102 as of November 17th. This net worth evaluation does not reflect any other investments that Ms. Turney may own. Learn More about Patricia A. Turney's net worth.
How do I contact Patricia A. Turney?: The corporate mailing address for Ms. Turney and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Patricia A. Turney's contact information.
Has Patricia A. Turney been buying or selling shares of Arcutis Biotherapeutics?: Patricia A. Turney has not been actively trading shares of Arcutis Biotherapeutics over the course of the past ninety days. Most recently, Patricia A. Turney sold 831 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $15.26, for a transaction totalling $12,681.06. Following the completion of the sale, the senior vice president now directly owns 62,862 shares of the company's stock, valued at $959,274.12. Learn More on Patricia A. Turney's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Patricia Turney (SVP), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, insiders at the sold shares 17 times. They sold a total of 125,351 shares worth more than $1,161,310.05. The most recent insider tranaction occured on November, 11th when Director Terrie Curran sold 8,687 shares worth more than $94,253.95. Insiders at Arcutis Biotherapeutics own 9.5% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 11/11/2024.

Patricia A. Turney Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2023	Sell	831	$15.26	$12,681.06	62,862
3/2/2023	Sell	1,432	$15.83	$22,668.56	45,693
2/28/2023	Sell	936	$16.17	$15,135.12	47,125
3/4/2022	Sell	993	$16.86	$16,741.98

Patricia A. Turney Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $9.26

$9.11

$10.04

50 Day Range

MA: $9.62

$8.31

$10.87

2 Week Range

Now: $9.26

$1.76

$13.17

Volume

3,018,887 shs

Average Volume

2,360,436 shs

Market Capitalization

$1.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18